Ortho gets CE mark for slides that run 2 IVD tests off a single blood sample

Ortho says its dual-test slides can increase productivity while maintaining the same lab footprint. (Ortho)

Ortho Clinical Diagnostics has received a CE mark for its new multitest platform that allows laboratories to run two in vitro diagnostic tests simultaneously on one slide.

The company’s Vitros XT MicroSlide employs digital optics to increase productivity while requiring less blood be taken from patients, which Ortho described as important for vulnerable patients and those with venous access issues.

The individual, dual-test slides include paired assays for blood urea nitrogen and creatinine ratios; triglycerides and cholesterol; and glucose and calcium levels, all for use on the Vitros XT 7600 Integrated System. The platform is currently under review by the FDA.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In a statement, Ortho said the system can improve turnaround time, and simplify inventory management and storage space.

RELATED: FDA approves Ortho’s next-generation Vitros HIV combo test

Late last year, the FDA approved Ortho’s HIV combination diagnostic—which detects both HIV-1 and HIV-2 antibodies, as well as the p24 antigen—for use on the Vitros 5600 system. The company described the combination test as being able to detect HIV-1 infections earlier than previous generations of the diagnostic.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.